Abstract 598TiP
Background
Lung cancer is currently the leading cause of death in cancer patients, non-small cell lung cancer (NSCLC) accounts for 80%-85% and the morbidity is increasing. About 70% of the cases have reached the advanced stage at the time of diagnosis. In some patients, the ECOG performance status (PS) score rates from 2 to 4 with worse prognosis and tolerance. Hence, Prof. Zhou's team defined the concept of "advanced severe lung cancer" in 2017. Currently, most guidelines recommend EGFR-TKIs as first-line treatment for EGFR mutation-positive (19del and L858R) patients. However, PS 2-4 patients were not included in most clinical trials. Thus, the efficacy and safety of EGFR-TKIs for PS 2-4 patients are still unknown in the real world. Aumolertinib is a third-generation EGFR-TKI independently developed in China with lower incidence of adverse events, which may be a better choice for advanced severe lung cancer patients. Thus, this study was designed to explore the efficacy and safety of aumolertinib in the first-line treatment of advanced non-small cell lung cancer patients of PS 3 with EGFR mutations. This may provide valuable hints for clinical applications.
Trial design
A total of 61 patients with EGFR mutations positive (19del and L858R) advanced non-small cell lung cancer with PS 3 will be enrolled and applying Aumolertinib 110 mg PO QD until progression. The primary endpoints are Objective Response Rate (ORR) and the duration of PS improved from 3 at baseline to 1. Secondary endpoints are progression-free survival (PFS), overall survival (OS), quality of life (QoL), disease control rate (DCR) and safety.
Clinical trial identification
NCT05826483.
Legal entity responsible for the study
The First Affiliated Hospital of Guangzhou Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract